Objective: To study the efficacy and safety of complex treatment with 2-ethyl-3-hydroxy-6-methylpyridine (mexidol forte 250) and venotonic drugs L-lysine aescinat and diosmin/hesperidin in patients with chronic cerebral venous insufficiency (CCVI).
Material And Methods: One hundred and twenty CCVI patients with clinical and ultrasonic signs of cerebral venous discirculation were studied. Patients were stratified into group 1 (=40) treated perorally with mexidol forte 250 and diosmin/hesperidin during 74 days in combination with two courses of L-lysine aescinat intravenously on the 1 and 30 days from baseline, group 2 (=40) treated with mexidol forte 250 and diosmin/hesperidin during 74 days, group 3 (=40) treated perorally with diosmin/hesperidin during 74 days.
Results And Conclusion: The efficacy and safety of the complex treatment of CCVI patients with venotonic drugs with the inclusion of mexidol forte 250 at a dose of 750 mg/day for 74 days is shown. The study demonstrates a significant positive effect of mexidol forte 250 on the dynamics of complaints and indicators of the neurological and psychoemotional status of patients. Monotherapy with the venotonic drug diosmin/hesperidin shows its insufficient efficacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro202112103157 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[The role of mitochondrial dysfunction in the stabilization of the glaucomatous process].
Vestn Oftalmol
September 2024
West Siberian Institute of Postgraduate Medical Education, Tyumen, Russia.
Unlabelled: Many key aspects of retinal ganglion cell (RGC) neurodegeneration in glaucoma are associated with mitochondrial dysfunction. Understanding the mechanisms and relationships between structural and functional changes in mitochondria would be beneficial for developing mitochondria-targeted therapeutic strategies to protect RGCs from glaucomatous neurodegeneration.
Purpose: This study determines the extent of mitochondrial dysfunction in patients with primary open-angle glaucoma (POAG) and evaluates the potential for stabilizing the glaucomatous process by improving mitochondrial functional activity and energy production by therapy with Mexidol and Mexidol FORTE 250.
[Results of a cohort single-center randomized study of the modulating effect of the drug Mexidol in the rehabilitation of patients who suffered acute cerebral insufficiency].
Zh Nevrol Psikhiatr Im S S Korsakova
April 2024
Clinical Institute of the Brain, Berezovsky, Russia.
Article Synopsis
- The study aimed to evaluate the impact of Mexidol on rehabilitation for patients who experienced acute cerebral insufficiency due to stroke or brain injury.
- The research involved 60 patients divided into two groups: one received traditional therapy plus Mexidol, while the control group received standard therapy alone.
- Results showed the Mexidol group saw notably reduced anxiety and depression, improved mobility, and suggested enhancement in cognitive functions compared to the control group, indicating the potential benefits of Mexidol as an adjuvant therapy.
[Neurometabolic therapy of mild cognitive impairment in patients with chronic cerebral ischemia].
Zh Nevrol Psikhiatr Im S S Korsakova
March 2024
Nizhny Novgorod Regional Clinical Hospital named after. N.A. Semashko, N. Novgorod, Russia.
Objective: To evaluate the effect of a sequential therapy regimen with Mexidol (500 mg injections intravenously for 14 days) and Mexidol FORTE 250 (250 mg tablets 3 times a day for 60 days) on higher cortical functions in patients with moderate cognitive disorders in chronic cerebral ischemia.
Material And Methods: A comparative, prospective study included 63 patients with chronic cerebral ischemia with moderate cognitive impairment. All patients received basic therapy aimed at reducing risk factors (antihypertensive, antithrombotic drugs as indicated).
[Efficacy of Mexidol in the correction of postcovid syndrome in patients with chronic cerebrovascular diseases].
Zh Nevrol Psikhiatr Im S S Korsakova
June 2023
Razumovsky Saratov State Medical University, Saratov, Russia.
Objective: To evaluate the effectiveness of sequential therapy with Mexidol and Mexidol FORTE 250 in the correction of postcovoid syndrome (PKS) in patients with chronic cerebrovascular diseases (CVD).
Material And Methods: The analysis of the results of examination and treatment of 110 patients with CVD who underwent COVID-19 was carried out. Patients of the main group (OH, =55) received Mexidol (5 ml IV drip for 14 days, followed by the transition to the tablet form of Mexidol FORTE 250 1 table 3 times/day for 2 months); 55 patients of the comparison group (GS) did not receive antioxidants.
[Clinico-psychological profile and life quality of patients with post-COVID syndrome].
Zh Nevrol Psikhiatr Im S S Korsakova
April 2023
Tver State Medical University, Tver, Russia.
Objective: To study clinico-psychological profile and life quality of patients with post-COVID syndrome.
Material And Methods: We examined 162 patients aged 24-60 years with confirmed SARS-CoV-2 infection which having symptoms that served as the basis for the diagnosis of post-COVID syndrome. Patients underwent general neurological and somatic examination with allocation of the corresponding neurological syndromes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!